Cogent Biosciences, Inc.
COGT· Nasdaq
COGTCogent Biosciences, Inc.
Filed Aug 10, 2026 · 10-Q · 41 days after period end · 0001193125-26-342393
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Net Income | -$96.41M | -$73.53M | -$58.95M | -$44.08M |
| EPS Diluted | -$0.52 | -$0.53 | -$0.59 | -$0.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cogent Biosciences, Inc. · CIK 1622229 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end
